Search Results
Facet (Page)
Refine Your Search
Audiences
Content Formats
Sections
News Release
Researchers are asking if the precision medicine approach will reduce or eliminate the role that race plays in prescribing drugs and in health care overall.
… the complex interplay of ancestry, health, disease and drug response. … In a May 26 New England Journal of Medicine … prescribing drugs and in health care overall. "We focus on drug therapies because that's where the precision medicine … imprecise prescribing practices. This means including in drug studies people from diverse social, racial and ethnic, …
News Release
A repurposed cancer drug appears to reduce the severity of lesions and pain experienced by people with Proteus syndrome
… Jeannine Mjoseth … A repurposed cancer drug appears to reduce the severity of lesions and pain … people with Proteus syndrome, a rare genomic disease. The drug, miransertib, was well tolerated, even in children, … are some initial, though unconfirmed, indications that the drug had a beneficial effect on symptoms of Proteus …
News Release
SJS/TEN is a severe drug reactions that affect the skin, and one of the most severe of adverse reactions affecting any system in the body
… Necrolysis (SJS/TEN). SJS/TEN is the severest of adverse drug reactions that affect the skin, and one of the most … organized a workshop , in collaboration with the Food and Drug Administration (FDA) and other NIH institutes, to … factors that predispose patients to severe immune mediated drug reactions like SJS/TEN, as well as studying the …
For Patients and Families
​Pharmacogenomics combines the science of how drugs work, called pharmacology, with the science of the human genome, called genomics.​
… genetic makeup, or genome, to choose the drugs and drug doses that are likely to work best for that particular … genetic makeup, or genome, to choose the drugs and drug doses that are likely to work best for that particular … drugs have been developed with the idea that each drug works pretty much the same in everybody. But genomic …
News Release
NIH researchers have identified a gene that makes yeast resistant to a lethal toxin.
Staff
Dr. Julie Segre is chief and a senior investigator in the Translational and Functional Genomics Branch at the National Human Genome Research Institute.
​
… tools to track hospital-acquired infections of multi-drug resistant organisms, including the NIH's recent … reconstructed a polymicrobial outbreak of multi-drug resistant Acinetobacter baumannii that swept through the … microbiome, bacterial pathogens, DNA sequencing, drug resistence … Dr. Julie Segre is chief and a senior …
News Release
A team from the NIH has surmounted a major obstacle to testing potential drug therapies for a rare, genetic condition called Gaucher disease.
… has surmounted a major obstacle to testing potential drug therapies for a rare, genetic condition called Gaucher … of the disease. Using this model, they have now tested a drug compound that has successfully corrected the … patients with Parkinson's disease." … Testing Potential Drug Therapies … Related Content … NIH researchers use a new …
News Release
Investigators with The Cancer Genome Atlas Research Network have identified new potential therapeutic targets for a major form of bladder cancer.
… remodeling. Overall, the researchers identified potential drug targets in 69 percent of the tumors evaluated. They … affecting different organs look very similar. As targeted drug agents go through preclinical and clinical development, … Content … TCGA bladder cancer study reveals potential drug targets, similarities to several cancers … Investigators …
Educational Resources
Pharmacogenomics is a branch of pharmacology concerned with using DNA and amino acid sequence data to inform drug development and testing.
… with using DNA and amino acid sequence data to inform drug development and testing. … Amino Acids, Deoxyribonucleic … with using DNA and amino acid sequence data to inform drug development and testing. … Educational Resources …
News Release
NIH researchers have identified a treatment that significantly decreases the risk of stroke in children with a rare genetic disease called Deficiency of Adenosine Deaminase Type 2 (DADA2).
… reason. … Benefits of the Treatment … Anti-inflammatory drug halts strokes in children with rare disease … NIH …